Heron Therapeutics is trading 5.66% down at $0.30, with no fresh company-specific announcement identified for August 26, 2026.
- Its latest material company news was the August 10 earnings update, which included withdrawn 2026 guidance, CINVANTI patent-related uncertainty, and a strategic review.
- Those issues remain background risks but do not clearly explain today’s intraday decline.
- The broader biotech sector is higher, so sector momentum does not appear to be driving the drop.